Recent advances in efficacy and safety evaluation of adalimumab in non-infectious uveitis
10.3760/cma.j.cn115989-20210705-00394
- VernacularTitle:阿达木单抗在非感染性葡萄膜炎中的疗效及安全性评估研究进展
- Author:
Qi GUO
1
;
Yandong WANG
Author Information
1. 中山大学中山眼科中心 眼科学国家重点实验室 广东省眼科视觉科学重点实验室，广州 510060
- Keywords:
Adalimumab;
Non-infection uveitis;
Efficacy;
Safety
- From:
Chinese Journal of Experimental Ophthalmology
2023;41(7):708-712
- CountryChina
- Language:Chinese
-
Abstract:
Non-infectious uveitis (NIU) is a serious sight-threatening disease caused by chronic inflammation and its complications.First-line treatment of NIU consists of topical and/or systemic corticosteroids and/or immunosuppressive drugs.Tumor necrosis factor-α inhibitors are recommended in cases of ineffectiveness or intolerance to conventional treatment of NIU.Adalimumab is a fully human monoclonal antibody that is widely used in the treatment of uveitis.Adalimumab is very effective in the treatment of NIU in several prospective and retrospective studies.Adalimumab has also been shown to be safe and effective in the treatment of NIU associated with various systemic diseases in many studies.The application of adalimumab in children, pregnant women, lactating women and other special populations has shown clear efficacy and acceptable side effects.The long-term safety of adalimumab is relatively stable, and no new adverse events have been reported.Compared with other tumor necrosis factor-α inhibitors, adalimumab also has a clear efficacy and better tolerability.This article reviewed the efficacy and safety of adalimumab in the treatment of NIU.
